Johnson & Johnson (NYSE: JNJ) closed Friday at $234.34, posting a 1.13% gain for the session and a weekly advance of approximately 3.4%. The stock outperformed the broader S&P 500 ahead of the Memorial Day holiday, as investors rotated into healthcare names amid a broader market rally that saw the Dow Jones Industrial Average hit a new record high.
Key Catalysts Behind the Move
The week's gains were driven by two significant developments. First, China’s National Medical Products Administration approved J&J’s nipocalimab for the treatment of generalized myasthenia gravis (gMG) in patients aged 12 and older. This autoimmune disorder causes muscle weakness and fatigue, and the approval opens a competitive market where rivals such as Hansoh Pharmaceutical Group, Zai Lab, and Argenx already have products. J&J has not yet disclosed launch timing or pricing strategy for the Chinese market.
Second, J&J MedTech announced a partnership with Abu Dhabi’s health regulator to standardize operating rooms using its Polyphonic digital surgery platform. The initiative involves collaborations with Amazon Web Services and NVIDIA. Hani Abouhalka, company group chair for surgery at J&J MedTech, emphasized that “no single company, hospital, or developer can do this alone,” highlighting the collaborative nature of the project.
Earnings Outlook and Upcoming Events
The stock’s recent strength is also rooted in J&J’s April earnings report, which led to an upgraded 2026 forecast. The company now expects reported sales of $100.8 billion at the midpoint and adjusted earnings per share of $11.55. CEO Joaquin Duato called the first quarter a “strong start to 2026,” citing recent approvals for ICOTYDE in plaque psoriasis and VARIPULSE Pro in Europe as potential long-term growth drivers.
Investors will have the opportunity to hear from management on Wednesday, May 27, when J&J executives speak at Bernstein’s Strategic Decisions Conference at 11:00 a.m. ET.
Market Context and Risks
The broader market backdrop remains supportive. The S&P 500 notched its eighth consecutive weekly gain, with nine of 11 major sectors ending higher on Friday, according to Reuters. Healthcare was among the top-performing sectors. James St. Aubin, chief investment officer at Ocean Park Asset Management, noted that “earnings season looked really good” and that recent economic data has been “pretty solid,” with only a few outliers.
However, risks remain. J&J cautions that the benefits from its Abu Dhabi digital surgery initiative may take longer than expected or may not materialize at all. The company also faces competition, regulatory hurdles, and pricing pressures. A slow rollout in China, new pricing headwinds, or an upside surprise in inflation could make last week’s gains appear overdone. The Personal Consumption Expenditures price index, due May 28, will be a key data point for markets.
U.S. markets will be closed Monday for Memorial Day, with trading resuming Tuesday. The shortened week will see investors focus on the PCE inflation data and J&J’s conference appearance.
